Immix Biopharma, Inc.(IMMX)

POST12.700.000.00%19:48 EDT

12.70+0.39+3.17%

CommunityCommunity
NewsNews
ProfileProfile
AnnouncementsAnnouncements

- Immix Biopharma Highlights NXC-201 CAR-T Data in Relapsed/refractory AL Amyloidosis Trial Presentation
  Reuters · 09-03
  Immix Biopharma Highlights NXC-201 CAR-T Data in Relapsed/refractory AL Amyloidosis Trial Presentation
- Immix Biopharma Price Target Cut to $19.00/Share from $20.00 by Morgan Stanley
  Dow Jones · 08-12
  Immix Biopharma Price Target Cut to $19.00/Share from $20.00 by Morgan Stanley
- Morgan Stanley Adjusts PT on Immix Biopharma to $19 From $20, Maintains Overweight Rating
  MT Newswires Live · 08-11
  Morgan Stanley Adjusts PT on Immix Biopharma to $19 From $20, Maintains Overweight Rating
- Immix Biopharma Publishes Corporate Presentation on NXC-201 BCMA CAR-T in Relapsed/refractory AL Amyloidosis
  Reuters · 08-11
  Immix Biopharma Publishes Corporate Presentation on NXC-201 BCMA CAR-T in Relapsed/refractory AL Amyloidosis
- Immix Biopharma is Maintained at Buy by HC Wainwright & Co.
  Dow Jones · 08-10
  Immix Biopharma is Maintained at Buy by HC Wainwright & Co.
- Analysts Are Bullish on These Healthcare Stocks: Immix Biopharma (IMMX), Ardelyx (ARDX)
  TIPRANKS · 08-10
  Analysts Are Bullish on These Healthcare Stocks: Immix Biopharma (IMMX), Ardelyx (ARDX)
- Immix Biopharma, Inc. : H.c. Wainwright Raises Target Price to $25 from $20
  THOMSON REUTERS · 08-10
  Immix Biopharma, Inc. : H.c. Wainwright Raises Target Price to $25 from $20
- Immix Biopharma, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary
  Reuters · 08-08
  Immix Biopharma, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary
- Immix Biopharma Q2 FY26 Net Loss Widens to USD 11.56 Million; G&A Expense More than Doubled to USD 7.12 Million
  Reuters · 08-08
  Immix Biopharma Q2 FY26 Net Loss Widens to USD 11.56 Million; G&A Expense More than Doubled to USD 7.12 Million
- Immix Biopharma, Inc. Expected to Post a Loss of 18 Cents a Share - Earnings Preview
  Reuters · 08-05
  Immix Biopharma, Inc. Expected to Post a Loss of 18 Cents a Share - Earnings Preview
- Immix Biopharma to Attend Morgan Stanley Global Healthcare Conference, Host Investor Meetings
  Reuters · 08-04
  Immix Biopharma to Attend Morgan Stanley Global Healthcare Conference, Host Investor Meetings
- Immix Biopharma Initiated at Buy by Needham
  Dow Jones · 07-22
  Immix Biopharma Initiated at Buy by Needham
- Needham Initiates Immix Biopharma at Buy With $21 Price Target
  MT Newswires Live · 07-22
  Needham Initiates Immix Biopharma at Buy With $21 Price Target
- Immix Biopharma Inc : Needham Initiates Coverage with Buy Rating; Target Price $21
  THOMSON REUTERS · 07-22
  Immix Biopharma Inc : Needham Initiates Coverage with Buy Rating; Target Price $21
- Immix Biopharma Terminates Richard Graydon Employment
  Reuters · 07-20
  Immix Biopharma Terminates Richard Graydon Employment
- Immix Biopharma - Richard Graydon Terminated from Immix Biopharma as of July 17, 2026 - SEC Filing
  THOMSON REUTERS · 07-20
  Immix Biopharma - Richard Graydon Terminated from Immix Biopharma as of July 17, 2026 - SEC Filing
- Immix Biopharma Posts Corporate Presentation Highlighting Nxc-201 CAR-T in Relapsed/refractory AL Amyloidosis
  Reuters · 07-03
  Immix Biopharma Posts Corporate Presentation Highlighting Nxc-201 CAR-T in Relapsed/refractory AL Amyloidosis
- Immix Biopharma Inc : Bofa Global Research Initiates Coverage With Buy Rating; Price Objective $27
  THOMSON REUTERS · 06-18
  Immix Biopharma Inc : Bofa Global Research Initiates Coverage With Buy Rating; Price Objective $27
- BofA Initiates Immix Biopharma at Buy With $27 Price Target
  MT Newswires Live · 06-18
  BofA Initiates Immix Biopharma at Buy With $27 Price Target
- Immix Biopharma Initiated at Outperform by LifeSci Capital
  Dow Jones · 06-18
  Immix Biopharma Initiated at Outperform by LifeSci Capital
Company Profile
Company Name
Immix Biopharma, Inc.
Market
NASDAQ
Establishment Date
- -
Employees
- -
Office Location
- -
Website
http://www.immixbio.com
Zip Code
- -
Phone
- -
Fax
- -
Introduction
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and immune-dysregulated diseases in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and colorectal cancer; and NXC-201 for relapsed/refractory multiple myeloma. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.
- 08-14
  Beneficial Ownership Change
  Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors
  Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors
- 08-13
  Beneficial Ownership Change
  Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
  Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
- 08-07
  Quarterly Report
  Form 10-Q - Quarterly report [Sections 13 or 15(d)]
  Form 10-Q - Quarterly report [Sections 13 or 15(d)]
- 07-20
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report
- 06-05
  Beneficial Ownership Change
  Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
  Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
- 05-29
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report
- 05-21
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report
- 05-21
  [Supp]Public Prospectus
  Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses
  Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses
- 05-21
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report
- 05-15
  Beneficial Ownership Change
  Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
  Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
- 05-07
  Quarterly Report
  Form 10-Q - Quarterly report [Sections 13 or 15(d)]
  Form 10-Q - Quarterly report [Sections 13 or 15(d)]
- 05-05
  Beneficial Ownership Change
  Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
  Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
- 03-30
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report
- 03-27
  [Rev.]Annual Report
  Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
  Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
- 03-25
  Employee Stock Ownership
  Form S-8 - Securities to be offered to employees in employee benefit plans
  Form S-8 - Securities to be offered to employees in employee benefit plans

1D
5D
Day
Week
Month

Loading ...

High

12.77

Open

12.08

Volume%

1.31

Low

11.91

12.31

T/O Rate

2.82%

To The Moon

Immix Biopharma, Inc.(IMMX)

Company Profile

Most Discussed